NGM·Healthcare·$70M·#303 / 520 in Healthcare

MNOV MediciNova, Inc.

37HIGH RISK

CATEGORY BREAKDOWN

GROWTH0
QUALITY0
STABILITY100
VALUATION0
GOVERNANCE48

METRIC BREAKDOWN

Revenue Growth (YoY)

Year-over-year revenue growth rate

-100.0%
0

> 50% strong

Gross Margin

Revenue retained after direct costs

N/A
0

> 50% strong

Cash Runway

Months of cash at current burn rate

46 months
100

> 24 months ideal

Debt / Equity

Total debt relative to shareholder equity

0.4%
100

< 25% strong

Price / Sales

Market cap relative to trailing revenue

171.2x
0

< 3x strong

Rule of 40

Growth rate plus operating margin

N/A
0

> 40 excellent

Insider Ownership

Percentage of shares held by insiders

2.9%
23

> 20% strong

Share Dilution (12M)

Share count increase over last 12 months

+0.4%
98

< 5% ideal

5 more metrics available

Unlock all 8 metrics, score history, watchlist, and side-by-side comparison.

Try Free for 30 Days

AI ANALYSIS REPORT

AI-GENERATED

BUSINESS SUMMARY

MediciNova, Inc. (MNOV) is a healthcare company trading on NGM with a market capitalization of $70M. The company currently carries a HIGH RISK rating of 37/100, flagging significant fundamental concerns. The fundamental profile shows significantly declining revenue at -100.0% year-over-year, paired with unavailable margin data at N/A. The balance sheet shows minimal leverage with a very low debt-to-equity ratio, and the company has strong cash position with 3+ years of runway.

VERDICT

MNOV scores 37/100 — the fundamentals flag multiple areas of concern. Only suitable for investors with high risk tolerance and a specific catalyst thesis. This report is based on the latest available financial data and is intended as a starting point for research, not a buy or sell recommendation.

MARKET OPPORTUNITY

In the healthcare sector, cash runway and pipeline progress are critical metrics. Revenue quality depends on whether income comes from product sales, partnerships, or milestones. MediciNova, Inc. operates with low insider ownership of 2.9%, which may indicate limited management alignment, which provides a signal about management's confidence in the company's direction. At a market cap of $70M, the company is very richly valued at over 20x price-to-sales, pricing in significant future growth at 171.2x P/S. The combination of these factors positions MNOV as a higher-risk position that requires careful due diligence before considering an investment.

REVENUE QUALITY

Revenue growth stands at -100.0% year-over-year, which is below the typical small-cap growth rate. Gross margins of N/A are thin and may compress further under competitive pressure. Cash runway of 46 months provides a comfortable buffer for executing on growth plans.

COMPETITIVE ADVANTAGE

Evaluating MediciNova, Inc.'s competitive position requires looking beyond the numbers. Insider ownership at 2.9% is relatively low, which may indicate that management's interests are less aligned with shareholders. The margin structure suggests the company operates in a competitive market where differentiation is harder to maintain. Share count management has been reasonable. Investors should research the specific sources of competitive advantage — patents, customer switching costs, scale economies, or brand — that could protect margins over time.

GROWTH THESIS

MNOV presents a speculative fundamental profile that requires a specific thesis to justify investment. The elevated 171.2x P/S ratio means significant growth is already priced in — execution must be strong to justify the premium. Key catalysts to watch include: revenue growth trajectory over the next 2-3 quarters, margin expansion or contraction, and any changes in insider buying or selling activity.

KEY RISKS

Execution risk is significant — many small-cap companies in this sector fail to transition from growth to profitability. Declining revenue (-100.0% YoY) is a fundamental concern that could signal loss of market share or structural headwinds. As a micro-cap stock, liquidity risk is a factor — wider bid-ask spreads and lower trading volumes can amplify price moves. Small-cap stocks carry inherently higher risk than large-caps, including limited analyst coverage, lower institutional ownership, and higher sensitivity to market downturns. Always conduct thorough due diligence beyond quantitative metrics.

Full AI Report available

Unlock the complete analysis including market opportunity, revenue quality, competitive moat, growth thesis, and risk assessment.

Try Free for 30 Days

Report generated: Mar 26, 2026

SCORE HISTORY

Track how this score changes over time. Start your free trial to see the full score trend chart.

SCORE ALERT

Get notified when MNOV's score changes by 5+ points.

DATA INFO

Last updated: Mar 11, 2026

Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.